WallStreetZenWallStreetZen

NASDAQ: ARAY
Accuray Inc Stock

$2.80+0.10 (+3.7%)
Updated Sep 25, 2023
ARAY Price
$2.80
Fair Value Price
$3.71
Market Cap
$270.45M
52 Week Low
$1.81
52 Week High
$4.30
P/E
-28x
P/B
5.04x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$447.61M
Earnings
-$9.28M
Gross Margin
34.4%
Operating Margin
-1.52%
Profit Margin
-2.1%
Debt to Equity
7.93
Operating Cash Flow
$16M
Beta
1.12
Next Earnings
Oct 31, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ARAY Overview

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARAY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARAY ($2.80) is undervalued by 24.61% relative to our estimate of its Fair Value price of $3.71 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ARAY ($2.80) is significantly undervalued by 24.61% relative to our estimate of its Fair Value price of $3.71 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ARAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARAY due diligence checks available for Premium users.

Be the first to know about important ARAY news, forecast changes, insider trades & much more!

ARAY News

Valuation

ARAY fair value

Fair Value of ARAY stock based on Discounted Cash Flow (DCF)
Price
$2.80
Fair Value
$3.71
Undervalued by
24.61%
ARAY ($2.80) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARAY ($2.80) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARAY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-28x
Industry
49.2x
Market
14.28x

ARAY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.04x
Industry
3.53x
ARAY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARAY's financial health

Profit margin

Revenue
$118.3M
Net Income
-$2.6M
Profit Margin
-2.2%
ARAY's Earnings (EBIT) of -$6.79M... subscribe to Premium to read more.
Interest Coverage Financials
ARAY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$479.2M
Liabilities
$425.6M
Debt to equity
7.93
ARAY's short-term assets ($338.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARAY's short-term assets ($338.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARAY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$8.9M
Investing
-$8.0M
Financing
-$522.0k
ARAY's operating cash flow ($15.54M)... subscribe to Premium to read more.
Debt Coverage Financials

ARAY vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
ARAY$270.45M+3.70%-28.00x5.04x
ANIK$270.68M+1.09%-12.09x0.99x
VMD$268.80M-2.10%36.84x2.57x
CERS$274.82M+1.33%-5.43x5.41x
ZIMV$258.66M+0.83%-3.09x0.36x

Accuray Stock FAQ

What is Accuray's quote symbol?

(NASDAQ: ARAY) Accuray trades on the NASDAQ under the ticker symbol ARAY. Accuray stock quotes can also be displayed as NASDAQ: ARAY.

If you're new to stock investing, here's how to buy Accuray stock.

What is the 52 week high and low for Accuray (NASDAQ: ARAY)?

(NASDAQ: ARAY) Accuray's 52-week high was $4.30, and its 52-week low was $1.81. It is currently -34.87% from its 52-week high and 54.7% from its 52-week low.

How much is Accuray stock worth today?

(NASDAQ: ARAY) Accuray currently has 96,590,033 outstanding shares. With Accuray stock trading at $2.80 per share, the total value of Accuray stock (market capitalization) is $270.45M.

Accuray stock was originally listed at a price of $28.47 in Feb 8, 2007. If you had invested in Accuray stock at $28.47, your return over the last 16 years would have been -90.17%, for an annualized return of -13.49% (not including any dividends or dividend reinvestments).

How much is Accuray's stock price per share?

(NASDAQ: ARAY) Accuray stock price per share is $2.80 today (as of Sep 25, 2023).

What is Accuray's Market Cap?

(NASDAQ: ARAY) Accuray's market cap is $270.45M, as of Sep 27, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Accuray's market cap is calculated by multiplying ARAY's current stock price of $2.80 by ARAY's total outstanding shares of 96,590,033.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.